E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
exacerbation of Cystic Fibrosis |
|
E.1.1.1 | Medical condition in easily understood language |
worsening of Cystic Fibrosis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- to determine the optimal dose and frequency of cysteamine in exacerbations of CF-associated lung disease - to determine the best questionnaire for evaluation of clinical benefit arising from use of cysteamine in exacerbations of CF-associated lung disease - to determine the effects of treatment with cysteamine on safety parameters |
|
E.2.2 | Secondary objectives of the trial |
to determine the effects of treatment with cysteamine on an exacerbation of CF-associated lung disease for each of the following: - sputum IL8 and neutrophil elastase levels - forced expiratory volume in the first second (FEV1) - weight - C-reactive protein (CRP) - blood leukocyte count - assessment of blood and sputum cysteamine levels |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. CF-associated lung disease with documented history of chronic infection with Gram-negative organism(s) 2. Established patient of the Principal Investigator's CF Multi-Disciplinary team 3. Age equal or greater than 18 years 4. Weight equal or more than 40 Kg 5. FEV1 more than 30% of predicted within the 6 months prior to study exacerbation 6. At baseline visit: experiencing a new exacerbation of CF associated lung disease requiring treatment that includes an aminoglycoside antibiotic 7) Females of childbearing potential will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first study drug dose continuing through 28 days after the last study drug dose, or using one of the following highly effective contraceptive (i.e. results in <1% failure rate when used consistently and correctly) methods in this trial: a. intrauterine device (IUD); b. surgical sterilization of the partner (vasectomy for 6 months minimum); c. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal); d. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable); e. intrauterine hormone releasing system (IUS); f. bilateral tubal occlusion. Females of childbearing potential agree to remain sexually inactive or to keep the same birth control method for at least 28 days following the last dose. 9) A female of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to the first study drug dose: a. hysteroscopic sterilization; b. bilateral tubal ligation or bilateral salpingectomy; c. hysterectomy; d. bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first study drug dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. 10) A non-vasectomized male subject agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion 7 or 9. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male. 11) If male, agrees not to donate sperm from the first study drug dose until 90 days after dosing. 12) Willing and able to comply with all protocol requirements and procedures, including induction of sputum, if necessary 13) Willing and able to provide signed and dated informed consent |
|
E.4 | Principal exclusion criteria |
1. Hypersensitive to cysteamine or to any of the excipients 2. Hypersensitive to penicillamine 3. Transplant recipient |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Change from baseline in patient health-related questionnaires (CFRSD-CRISS, Jarad and Sequeiros Smptom Score Questionnaire - Change from baseline in sputum bacterial load of (a) total CFU per ml and per mg and (b) gram negative CFU per ml and per mg at Day 7, Day 14 and Day 21 following a CF exacerbation - Change from baseline in sputum IL8 and neutrophil elastase levels at Day 7, Day 14 and Day 21 following a CF exacerbation - Change from baseline to Day 7, Day 14 and Day 21 in FEV1, weight, CRP, blood leucocyte count and CFQ-R - Assessment of blood and sputum cysteamine levels at Day 14 - Patient Global Assessment of Exacerbation outcome |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
See section E.5.1. Primary End Points |
|
E.5.2 | Secondary end point(s) |
See section E.5.1 Primary end points |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
See section E.5.1 Primary End Points |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Italy |
Netherlands |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |